Holen Sie sich die Stockscreener-App
110.22
8.05%
8.21
Handel nachbörslich:
108.00
-2.22
-2.01%
Celcuity Inc Aktie (CELC) Neueste Nachrichten
Celcuity Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Transcript : Celcuity Inc., Q4 2025 Earnings Call, Mar 25, 2026 - marketscreener.com
Celcuity Q4 Earnings Call Highlights - Yahoo Finance
CELC: FDA priority review, strong trial data, and robust cash position set stage for 2026 launch - TradingView
Earnings call transcript: Celcuity beats Q4 2025 EPS forecast, stock rises - Investing.com
Celcuity Inc. (NASDAQ:CELC) Reports Q4 Earnings Beat and Key FDA Priority Review for Gedatolisib - ChartMill
Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Beats Estimates By $0.33 EPS - MarketBeat
CELCUITY ($CELC) Releases Q4 2025 Earnings - Quiver Quantitative
Celcuity Q4 Adjusted Loss Narrows - marketscreener.com
Celcuity Inc. reports release of fourth quarter and full year 2025 financial results and provides corporate update - marketscreener.com
Celcuity Inc. Reports Release Of Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Update - TradingView
BRIEF-Celcuity Q4 Adjusted EPS USD -0.73 Vs. IBES Estimate USD -1.04 - TradingView
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Celcuity earnings up next as breast cancer drug nears approval By Investing.com - Investing.com Canada
Why Celcuity’s Hot Stock Is Suddenly Cooling - TipRanks
Celcuity (CELC) Hits Fresh Record High on Stellar Breast Cancer Drug Trial Result - MSN
Aug Drivers: Is Celcuity Inc stock a smart retirement pick2026 Intraday Action & High Conviction Buy Zone Alerts - baoquankhu1.vn
Celcuity (CELC) Projected to Post Earnings on Monday - MarketBeat
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - AOL.com
Celcuity Inc.: Fundamental Analysis and Financial Ratings | 7VR | US15102K1007 - marketscreener.com
CELC Stock Price, Quote & Chart | CELCUITY INC (NASDAQ:CELC) - ChartMill
Aug Breakouts: Should I set a stop loss on Celcuity Inc2026 Sentiment & Risk Controlled Daily Plans - baoquankhu1.vn
Assessing Celcuity (CELC) Valuation After VIKTORIA-1 Data And New Analyst Buy Rating - Sahm
Celcuity (CELC) price target increased by 11.17% to 108.57 - MSN
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call - The Manila Times
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and ... - Bluefield Daily Telegraph
Why (CELC) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Needham & Company LLC Reiterates Buy Rating for Celcuity (NASDAQ:CELC) - MarketBeat
HighVista Strategies LLC Purchases New Position in Celcuity, Inc. $CELC - MarketBeat
49,281 Shares in Celcuity, Inc. $CELC Purchased by Granahan Investment Management LLC - MarketBeat
Celcuity publishes Phase 3 trial results in medical journal - Investing.com Nigeria
Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Celcuity prices $248.7M debt, stock offerings - MSN
What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For Shareholders - Yahoo Finance
90,000 Shares in Celcuity, Inc. $CELC Purchased by Boxer Capital Management LLC - MarketBeat
Apis Capital Advisors LLC Acquires New Holdings in Celcuity, Inc. $CELC - MarketBeat
The Bull Case For Celcuity (CELC) Could Change Following Strong VIKTORIA-1 Gedatolisib Phase 3 Data - simplywall.st
Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink Conference - MarketBeat
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - The Motley Fool
Celcuity: Undervalued Pipeline with Differentiated Clinical Profile Supports Buy Rating - TipRanks
15,000 Shares in Celcuity, Inc. $CELC Purchased by Aristides Capital LLC - MarketBeat
Wolfe Research Maintains Outperform on Celcuity Inc (CELC) Mar 12, 2026 - Meyka
Celcuity’s Gedatolisib Advances With Pivotal Data And FDA Priority Review - simplywall.st
Celcuity stock maintained at Outperform by Wolfe on efficacy outlook - Investing.com South Africa
Celcuity Stock Pre-Market (-0.2%): Needham Raises Target on Strong Data Publication - Trefis
Buyback Watch: Can Celcuity Inc ride the EV waveEarnings Risk Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Is Celcuity (CELC) Pricing Reflecting Its Sharp Rally And DCF-Heavy Discount? - simplywall.st
Assessing Celcuity (CELC) Valuation After Strong Recent Returns And Optimistic Growth Forecasts - Sahm
CELC: Gedatolisib demonstrates leading efficacy in breast cancer, with launch and global expansion underway - TradingView
CELC: Gedatolisib delivers record efficacy in breast cancer, with launch and global expansion plans advancing - TradingView
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):